Paul A. Frohna

Paul A. Frohna is an experienced executive in the biotech industry, currently serving as an independent board member at Accure Therapeutics. Paul has previously held leadership positions at FibroGen Inc., ImCheck Therapeutics, Accure Therapeutics, and Bioniz Therapeutics, where they were responsible for clinical research, data management, biostatistics, drug safety, and clinical pharmacology.

At Bioniz Therapeutics, Frohna served as Chief Medical Officer, responsible for the clinical, biometrics, and regulatory affairs activities to support the development of the company's portfolio of novel multi-cytokine inhibitors for immuno-oncology and immune-mediated diseases. Paul was also a member of the executive team responsible for corporate portfolio planning, fund-raising and licensing/partnerships.

Previously, Frohna served as Vice President of Clinical Development & Translational Medicine at Receptos, Inc., a subsidiary of Celgene. In this role, they were responsible for the clinical development of the company's lead candidate ozanimod for the treatment of autoimmune and inflammatory diseases.

Frohna has also served on the Advisory Board of the International Symposium on Hematology from 2011 to 2014. Paul holds a medical degree from Harvard Medical School.

Paul A. Frohna attended The University of Texas at Austin for their pharmacy degree. Paul then attended Georgetown University for their Doctor of Medicine (M.D.) in Internal Medicine. For their graduate studies, they attended the University of California, San Francisco in Epidemiology & Clinical Research. Lastly, they attended the University of Pennsylvania for their Doctor of Philosophy (Ph.D.) in Neuropharmacology.